← Leaderboards
Donald Bottaro
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionOncogenicPathway InteractionsNeoplasm MetastasisCell LineTumorCellsBaseTumorigenesisMalignant NeoplasmsRenal Cell CarcinomaResponseCell MotilityDesignAngiogenesisMolecularProteinsInhibitor/AntagonistStructureCollaborationsGenesPre-ClinicalBiologicalSignal Pathway
Grant awards (36)
Oncogenic Met Signaling in Urologic Malignancies$253,686
ZIA · FY2021 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$136,601
ZIA · FY2021 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$335,956
ZIA · FY2020 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$180,900
ZIA · FY2020 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$522,479
ZIA · FY2019 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$281,335
ZIA · FY2019 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$558,896
ZIA · FY2018 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$300,943
ZIA · FY2018 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$496,098
ZIA · FY2017 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$267,130
ZIA · FY2017 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$542,075
ZIA · FY2016 · CA · contact PI
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers$291,887
ZIA · FY2016 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$474,446
ZIA · FY2015 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$145,984
ZIA · FY2015 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$109,487
ZIA · FY2015 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$478,765
ZIA · FY2014 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$147,313
ZIA · FY2014 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$110,485
ZIA · FY2014 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$444,424
ZIA · FY2013 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$185,176
ZIA · FY2013 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$111,106
ZIA · FY2013 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$392,916
ZIA · FY2012 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$163,714
ZIA · FY2012 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$98,228
ZIA · FY2012 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$455,288
ZIA · FY2011 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$189,703
ZIA · FY2011 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$113,822
ZIA · FY2011 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$577,770
ZIA · FY2010 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$288,886
ZIA · FY2010 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$96,296
ZIA · FY2010 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$238,669
ZIA · FY2009 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$119,334
ZIA · FY2009 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$39,778
ZIA · FY2009 · CA · contact PI
Oncogenic Met Signaling in Urologic Malignancies$241,666
Z01 · FY2008 · CA · contact PI
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics$144,999
Z01 · FY2008 · CA · contact PI
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma$96,666
Z01 · FY2008 · CA · contact PI